NTLA-2001
AssetAlso called nexiguran ziclumeran
CRISPR-mediated disruption of hepatic TTR reduces transthyretin production and subsequent amyloid deposition.
- Stage
- Phase 3
- Modality
- Gene editing
- Target
- TTR
- 12
- Indications
- 3
- Trials
- 1
- Developer
2 trials are still running. Trial NCT06672237 updated in its registry on Nov 5, 2026. clinicaltrials.gov
Indications
12Familial amyloidosis
Phase 3, Active not recruiting, NCT06672237, clinicaltrials.gov, Nov 5, 2026
Hereditary amyloidosis
Phase 3, Active not recruiting, NCT06672237, clinicaltrials.gov, Nov 5, 2026
Hereditary neurodegenerative disease
Phase 3, Active not recruiting, NCT06672237, clinicaltrials.gov, Nov 5, 2026
9 more
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials3
- Evidence for its targets2
- Competitors8
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.